Bolt Biotherapeutics pulls in $54 mln Series B


San Francisco Bay Area-based Bolt Biotherapeutics, a biotechnology company focused on the immune system, has secured $54 million in Series B financing. Pivotal bioVenture Partners led the round with participation from Nan Fung Life Sciences, Novo Holdings and Vivo Capital.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!